Every Form 4 that Celularity Inc. (CELU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CELU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELU filings page.
The Philip & Daniele Barach Family Trust, a 10% owner of Celularity Inc., reported changes in its derivative positions. The trust’s option to purchase up to $2,000,000 in convertible notes, which were convertible into 1,807,229 shares of Class A common stock, expired pursuant to its terms on June 19, 2026 without any consideration paid. A related option to obtain up to 839,160 warrants also expired on that date. The filing also lists continuing holdings of warrants and convertible notes that are convertible into 3,707,457 and 1,807,229 shares of Class A common stock, respectively.
Celularity Inc ten percent owner reports expiration of financing options held through a family trust. The Philip & Daniele Barach Family Trust previously held options to purchase up to $2,000,000 in aggregate principal amount of convertible notes and to obtain up to 839,160 related warrants for Celularity Class A common stock.
These options expired according to their terms on June 19, 2026, and the expiration occurred with no consideration paid. The trust is or was the direct owner of all securities reported, while Philip Alan Barach is a trustee with independent voting and disposition power and may be deemed an indirect beneficial owner, subject to his pecuniary interest.
Celularity Inc’s major shareholder, Daniele Wolf Barach, reported changes in derivative positions held through the Philip & Daniele Barach Family Trust. Options to purchase up to $2,000,000 of convertible notes, and related rights to obtain 839,160 warrants, expired on June 19, 2026 with no consideration paid.
The trust continues to hold indirect derivative interests in warrants for 3,707,457 shares of Class A common stock at $2.00 per share, expiring on December 19, 2030, and convertible notes convertible into 1,807,229 shares at $1.66 per share, expiring on December 31, 2026. The reporting person may be deemed an indirect beneficial owner but disclaims beneficial ownership beyond any pecuniary interest.
Celularity Inc. executive Stephen Brigido reported the vesting and conversion of 821 restricted stock units into Class A Common Stock on April 13, 2026. These RSUs were part of a 3,281-unit grant made on April 13, 2022, of which 25% vested on this date.
To cover taxes on the vesting, 268 shares of Class A Common Stock were withheld at a price of $1.28 per share, leaving a net increase of 553 shares from this event. Following these transactions, Brigido directly holds 9,474 shares of Celularity Class A Common Stock.
Celularity Inc Senior Executive Vice President John R. Haines reported the vesting and conversion of 1,641 restricted stock units (RSUs) into 1,641 shares of Class A common stock. The RSUs are part of a 6,562-unit grant made on April 13, 2022, of which 25% vested on April 13, 2026.
To cover tax obligations on this RSU vesting, 583 shares of Class A common stock were withheld at a price of $1.28 per share. After these compensation-related transactions, Haines directly owns 30,179 shares of Celularity Class A common stock. Each RSU is the economic equivalent of one share of Class A common stock.
Celularity Inc Chief Executive Officer Robert J. Hariri reported routine equity compensation activity involving restricted stock units (RSUs). On April 13, 2026, 3,281 RSUs granted on April 13, 2022 vested and converted into 3,281 shares of Class A Common Stock, representing 25% of a 13,123-RSU award.
To cover tax obligations on this vesting, 1,182 shares of Class A Common Stock were withheld at $1.28 per share, a non–open-market disposition. Following these transactions, Hariri directly holds 2,853,553 shares of Celularity Class A Common Stock.
Celularity Inc. director Diane Parks reported receiving 30,000 restricted stock units (RSUs) on January 12, 2026 under the company’s 2021 Equity Incentive Plan. Each RSU represents a right to receive one share of Celularity’s Class A common stock, and this award vests immediately upon grant. After this transaction, she beneficially owns 520,021 shares of Class A common stock in direct ownership.
Celularity Inc. director Peter Diamandis reported an equity award under the company’s 2021 Equity Incentive Plan. On 01/12/2026, he received 20,385 restricted stock units (RSUs), each representing one share of Celularity’s Class A common stock, at a price of $0.00.
The RSUs vest immediately upon grant, meaning they become fully earned right away rather than over time. Following this award, Diamandis beneficially owns 394,150 shares of Class A common stock, all held directly.
Celularity Inc. reported that director Geoffrey Ling received a grant of 19,231 restricted stock units (RSUs) under the company’s 2021 Equity Incentive Plan on January 12, 2026. Each RSU represents one share of Celularity’s Class A common stock, and the RSUs vest immediately upon grant, meaning the shares are no longer subject to a vesting schedule. Following this equity award, Ling now beneficially owns 256,026 shares of Celularity Class A common stock in total, reflecting a routine update to his equity-based director compensation.
Celularity Inc. director Vincent LeVien reported receiving 28,847 restricted stock units (RSUs) of Class A common stock under the company’s 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of Class A common stock, and the filing states that these RSUs vest immediately upon grant as of 01/12/2026. After this equity award, LeVien beneficially owns 153,847 shares of Celularity Class A common stock in total, held directly.
Celularity Inc. director Geoffrey Ling reported receiving 19,231 restricted stock units (RSUs) of Class A common stock. These RSUs were granted under the company’s 2021 Equity Incentive Plan at no cash cost and each unit represents one future share. The RSUs will vest on the earlier of one year from the grant date or the next annual stockholder meeting, as long as he continues serving the company. After this award, Ling beneficially owns 256,026 shares and RSUs in total on a direct basis.
Celularity Inc. director Vincent LeVien reported an award of 28,847 shares of Class A common stock on January 12, 2026, coded as an "A" transaction for an acquisition at a price of $0 per share. These shares are in the form of restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Class A common stock.
The RSUs will vest and become exercisable on the earlier of the one-year anniversary of the grant date and the next annual stockholder meeting, as long as LeVien continues to provide service to the company through that date. Following this grant, he beneficially owns a total of 153,847 shares of Class A common stock in direct ownership.
Celularity Inc. director Peter Diamandis reported an equity award of 20,385 restricted stock units (RSUs) of Class A common stock on January 12, 2026. The RSUs were granted at a price of $0 per share under the Celularity Inc. 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Class A common stock.
The RSUs will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, as long as Diamandis continues to serve the company through that date. Following this grant, he directly holds a total of 394,150 Class A common shares and RSUs.
Celularity Inc. director Diane L. Parks received an award of 30,000 restricted stock units (RSUs) of Class A common stock on January 12, 2026, reported at a grant price of $0 per share. Each RSU represents the right to receive one share of Class A common stock.
The RSUs vest on the earlier of the one-year anniversary of the grant date and the next annual stockholder meeting, if she continues serving the company through that date. Following this grant, she beneficially owns 520,021 shares of Class A common stock, including the new RSUs granted under the 2021 Equity Incentive Plan.
Celularity Inc. (CELU) reported an equity award to a director. Director Diane Parks received 61,539 restricted stock units (RSUs) of Class A common stock on 11/19/2025 under the Celularity Inc. 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of Class A common stock, and the RSUs vest and become exercisable on the grant date at a price of $0.00 per share. Following this grant, Diane Parks beneficially owns 365,021 shares of Celularity Class A common stock in direct ownership.
Celularity Inc. (CELU) reported a new equity grant to a director. On 11/19/2025, the reporting person, who serves as a director of Celularity, received 3,699 shares of Class A common stock in the form of restricted stock units (RSUs) under the Celularity Inc. 2021 Equity Incentive Plan.
Each RSU represents a right to receive one share of Celularity's Class A common stock, and the RSUs vest and become exercisable on the date of grant. After this transaction, the director beneficially owns 3,699 Class A common shares directly.
Celularity Inc. (CELU) director Geoffrey Ling reported a grant of 44,379 restricted stock units (RSUs). The transaction occurred on 11/19/2025 and was reported on a Form 4 as an acquisition of Class A common stock at a stated price of $0.00 per share, reflecting an equity award rather than an open-market purchase.
Each RSU represents the right to receive one share of Celularity’s Class A common stock, and the RSUs vest and become exercisable on the grant date under the company’s 2021 Equity Incentive Plan. Following this award, Ling beneficially owns 111,795 shares of Class A common stock in direct form, aligning his interests more closely with those of shareholders.
Celularity Inc. (CELU) director Peter Diamandis reported an equity award of 47,042 restricted stock units (RSUs) of Class A common stock. Each RSU represents the right to receive one share of Celularity's Class A common stock. The RSUs were granted on 11/19/2025 under the Celularity Inc. 2021 Equity Incentive Plan and shall vest and become exercisable on the grant date, meaning they are not subject to a future service-based vesting schedule. The Form 4 shows the transaction price as $0.00, consistent with a typical director equity grant rather than an open-market purchase. Following this grant, Diamandis is reported to beneficially own 248,765 shares of Class A common stock in direct ownership.